Shopping Cart
Remove All
Your shopping cart is currently empty
Anti-ICOS ligand Antibody-FITC (1W488) is a FITC-conjugated Mouse antibody targeting ICOS ligand. Anti-ICOS ligand Antibody-FITC (1W488) can be used in FCM.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 25 T | $81 | 7-10 days | 7-10 days | |
| 100 T | $105 | 7-10 days | 7-10 days |
| Description | Anti-ICOS ligand Antibody-FITC (1W488) is a FITC-conjugated Mouse antibody targeting ICOS ligand. Anti-ICOS ligand Antibody-FITC (1W488) can be used in FCM. |
| Synonyms | LICOS, inducible T-cell co-stimulator ligand, ICOSLG, ICOS-L, ICOSL, ICOS ligand, GL50, CD275, B7RP-1, B7RP1, B7-h2, B7H2 |
| Ig Type | Mouse IgG1 |
| Clone | 1W488 |
| Reactivity | Human |
| Specificity | Human B7-H2/ICOSLG |
| Verified Activity | Flow cytometric analysis of ICOSLG(CD275) expression on RPMI8226 cells. |
| Application | |
| Recommended Dose | 10 μl/Test, 0.1 mg/ml |
| Antibody Type | Monoclonal |
| Host Species | Mouse |
| Construction | This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human ICOS Ligand / B7-H2 (rh ICOS Ligand / B7-H2; TMPY-01672; NP_056074.1; Met1-Ser258) and conjugated with FITC under optimum conditions, the unreacted FITC was removed. |
| Purification | Protein A |
| Appearance | Liquid |
| Formulation | PBS solution containing 0.5% BSA and 0.03%ProClin300 |
| Research Background | Inducible co-stimulator ligand (ICOSL), also known as B7-H2, is a member of the B7 family of co-stimulatory molecules related to B7-1 and B7-2. It is a transmembrane glycoprotein with extracellular IgV and IgC domains and binds to ICOS on activated T cells, thus delivers a positive costimulatory signal for optimal T cell function. The structural features of ICOSL are crucial for its costimulatory function. The present study shows that ICOSL displays a marked oligomerization potential, resembling more like B7-1 than B7-2. B7-H2-dependent signaling may play an active role in a proliferative response rather than in cytokine and chemokine production. The CD28/B7 and ICOS/B7-H2 pathways are both critical for costimulating T cell immune responses. Deficiency in either pathway results in defective T cell activation, cytokine production, and germinal center formation.Cancer ImmunotherapyCo-stimulatory Immune Checkpoint TargetsImmune CheckpointImmune Checkpoint Detection: AntibodiesImmune Checkpoint Detection: ELISA AntibodiesImmune Checkpoint Detection: FCM AntibodiesImmune Checkpoint Detection: WB AntibodiesImmune Checkpoint TargetsImmunotherapyTargeted Therapy |
| Conjucates | FITC |
| Others Formats | Unconjugated/APC/PE |
| Antibody Types Available | 4 |
| Immunogen | Recombinant Protein: Human ICOS Ligand / B7-H2 protein (TMPY-01672) |
| Antigen Species | Human |
| Biology Area | Cancer Drug Targets |
| Stability & Storage | Store at 2°C-8°C for 12 months, do not freeze. Keep away from direct sunlight. |
| Transport | Shipping with blue ice. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.